glp-1 colorectal cancer risk study november 2025 GLP-1s show 'mind-blowing' effect on Frontiers | Reassessing cancer risk
Description
Founders and investors see massive potential in the new drug class but funding is yet to flood startups in the sector.
Novo's Wegovy pill already has over 600,000 prescriptions since it was approved in December, and Foundayo doesn't require fasting which is a major differentiator
Excessive sweating affects some patients taking semaglutide and other GLP-1 medications
3094 in the Eastern District of Pennsylvania has grown to include over 1,800 active cases, with plai
